Latest Morphinans Stories
NEW YORK, Jan. 28, 2013 /PRNewswire/ -- Sunday's front page of The New York Times New York edition headlined, "F.D.A. Likely to Add Limits on Painkillers," an advisory panel to the Food and Drug Administration voted 19 to 10 to recommend increased restrictions on hydrocodone products, the country's most widely used narcotic painkillers. Painkillers now take the lives of more Americans than heroin and cocaine combined, and since 2008, drug-induced deaths have outstripped those from...
redOrbit Staff & Wire Reports - Your Universe Online A panel of medical experts is advising the US Food and Drug Administration (FDA) to tighten restrictions on painkillers that contain the substance hydrocodone – a move intended to make it more difficult to prescribe and, ideally, help to curb abuse of the addictive substance. According to Reuters, the panel voted 19-10 in favor of reclassifying all medications containing less than 15 milligrams of hydrocodone, which include...
Only 1 in 5 parents say they are very concerned about children, teens misusing narcotics, according to U-M's National Poll on Children's Health ANN ARBOR, Mich., Jan. 23, 2013 /PRNewswire-USNewswire/ -- Despite data on rising rates of abuse and overdoses of narcotic pain medicines across all age groups, in a new poll from the University of Michigan, most parents said they are not very concerned about misuse of these medicines by children and teens. In addition, parent support...
PARSIPPANY, N.J., Jan. 23, 2013 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that Actavis South Atlantic LLC, which was acquired by Watson in October, has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Oxymorphone Hydrochloride Extended-release Tablets. Actavis' ANDA product is a generic version of the currently marketed formulation of Endo Health Solutions' Opana(®) ER,...
RALEIGH, N.C., Jan. 22, 2013 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced today the completion of its study evaluating the safety and tolerability of BEMA Buprenorphine/Naloxone (BNX) in the treatment of opioid dependent patients. (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO ) "We are pleased with the outcome of this study," stated Dr. Andrew Finn, Executive Vice President of Product Development for BDSI. "Results...
CANTON, Mass., Jan. 17, 2013 /PRNewswire/ -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced the relocation of its corporate offices and laboratory facilities to Canton, Massachusetts from Cumberland, Rhode Island. The Company's lead development program is Oxycodone DETERx(®) (COL-003), a tamper-resistant, extended-release oxycodone product utilizing its proprietary DETERx(®...
PRINCETON, N.J., Jan. 15, 2013 /PRNewswire/ -- Neura Therapeutik announced today the securing of terms on NL-001, an abuse-deterrent, long-acting opioid analgesic and that studies conducted on NL-001 comply with recent FDA draft guidance. Issued last week, this guidance is intended to assist pharmaceutical companies who wish to develop abuse deterrent opioid formulations. Prescription opioids are a mainstay in the management of moderate-to-severe chronic pain. However abuse and...
ALBANY, New York, January 9, 2013 /PRNewswire/ -- New Market Research Report Added in MarketResearchReports.Biz Reports Database Opioids Market to 2018 - Increasing Concentration of Abuse-Resistant Branded Generics Alter Competitive Dynamics in this Flat Market [http://www.marketresearchreports.biz/analysis/158132 ] Leading business intelligence provider GBI Research [http://www.marketresearchreports.biz/publisher/2 ] has released its latest research report, entitled...
Sovereign Health of California has seen a drastic increase in number of patients seeking treatment for heroin addiction. Sovereign Health is committed to combating the spread of hepatitis C by treating heroin addiction through their innovative opiate addiction treatment plan and newly added technology enhanced aftercare monitoring program (T.E.A.M.). Los Angeles, CA (PRWEB) January 08, 2013 Heroin is the most common name for an illegal and often more potent form of morphine, a drug used...
NORTH LIBERTY, Iowa, Jan. 7, 2013 /PRNewswire/ -- KemPharm, Inc, a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that the United States Adopted Name (USAN) Council approved the use of the nonproprietary name, "benzhydrocodone," for its lead pain candidate, KP201. KP201 is in development for the treatment of acute moderate to moderately severe pain with a new drug application (NDA) expected...
